Return on Equity (ROE): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds ...

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Wall Street analysts forecast that Regeneron (REGN) will report quarterly earnings of $8.03 per share in its upcoming release, pointing to a year-over-year decline of 30.5%. It is anticipated that ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Regeneron Pharmaceuticals has a 52 week low of $481.58 and a 52 week high of $1,211.20. The stock has a market capitalization of $52.67 billion, a P/E ratio of 12.74, a price-to-earnings-growth ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron's first-quarter sales fell 4% year over year, while adjusted earnings per share dropped 14% lower. This is one of the most affordable large-cap biotech stocks today, but arguably for ...